By Sydney Lupkin, NPR
For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia.
The twice-a-day pill to be marketed by Bristol Myers Squibb will be called Cobenfy, though it had been referred to as KarXT during development. Its main advantage is that it appears to have fewer side effects than current medicines.
More here >
This post was originally published on this site